Announcement on Obtaining Approval for Chemical API Market Application Notification

Newland Pharmaceutical Co., Ltd.·July 23, 2026·2 pages

✨ AI Summary

Newland Pharma received approval from the National Medical Products Administration for its Amlodipine Besilate API. This approval signifies compliance with registration requirements, enriching the company's product portfolio and enhancing market competitiveness. The company anticipates increased market competitiveness due to this development.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 301277

Securities Abbreviation: Newland

Announcement No.: 2026-023

Newland Pharma Co., Ltd.

Announcement on Obtaining Approval for Chemical API Market Application Notification

The Company and all members of the Board of Directors guarantee that the content of this announcement is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

On July 21, 2026, Newland Pharma Co., Ltd. (hereinafter referred to as the "Company") received the "Chemical API Market Application Approval Notification" issued by the National Medical Products Administration for Amlodipine Besilate API. The relevant situation is hereby announced as follows:

I. Drug Information

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.